ABBV

AbbVie
Biotechnology · Health Care · as of 2026-11-20
Last close
$288.75
+1.8% on the session
1-year return
+27.7%
+35.7% over six months
Volatility
25.4%
annualized, trailing year
Max drawdown
-15.7%
worst peak to trough, 1y
What the numbers say

AbbVie is a biotechnology name in the health care sector. Over the past year it returned +27.7%, against +9.8% over three months and +1.2% over one. It trades 20.3% above its 200-day average, so the longer trend is confirming recent strength. Annualized volatility of 25.4% is moderate by single-stock standards.

Its worst peak-to-trough decline over the year was -15.7%, and it has traded a median $1.2B a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate -0.01 with the S&P 500 proxy, so it has been moving substantially on its own.

Where it ranks
Within Health Care#14 of 59
Stronger than 78% of its sector on the momentum profile
Across the whole index#33 of 497

How ABBV scores on all four profiles

Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 7 others in Biotechnology.

Start a free 7-day trial
Full metrics
1 day+1.8%
1 week-2.1%
1 month+1.2%
3 months+9.8%
6 months+35.7%
1 year+27.7%
12-1 momentum+26.2%
Volatility (1y, annualized)25.4%
Max drawdown (1y)-15.7%
Distance vs 200-day average+20.3%
Return per unit of risk1.09
Median daily dollar volume$1.2B
Free newsletter

Get ABBV when it shows up in a ranking

Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.

Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.